Limits...
Anti-HIV-1 activity of salivary MUC5B and MUC7 mucins from HIV patients with different CD4 counts.

Habte HH, de Beer C, Lotz ZE, Roux P, Mall AS - Virol. J. (2010)

Bottom Line: Cells were then cultured and viral replication was measured by a qualitative p24 antigen assay.The size, charge and immunoreactivity of mucins from HIV negative and positive individuals was also analysed by SDS-PAGE, Western blot and ELISA respectively.Size, charge and immunoreactivity differences between the mucins from HIV negative and positive individuals and among the mucins from HIV patients of different CD4 count was observed by SDS-PAGE, Western blot and ELISA.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Surgery, Division of General Surgery, University of Cape Town, Observatory, Cape 7925, South Africa.

ABSTRACT

Background: We have previously shown that MUC5B and MUC7 mucins from saliva of HIV negative individuals inhibit HIV-1 activity by 100% in an in vitro assay. The purpose of this subsequent study was to investigate whether MUC5B and MUC7 from saliva of HIV patients or with full blown AIDS had a similar inhibitory activity against the virus.

Methods: Salivary MUC5B and MUC7 from HIV patients with different CD4 counts (< 200, 200-400 and > 400) were incubated with HIV-1 prior to infection of the human T lymphoblastoid cell line (CEM SS cells). Cells were then cultured and viral replication was measured by a qualitative p24 antigen assay. The size, charge and immunoreactivity of mucins from HIV negative and positive individuals was also analysed by SDS-PAGE, Western blot and ELISA respectively.

Results: It was shown that irrespective of their CD4 counts both MUC5B and MUC7 from HIV patients, unlike the MUC5B and MUC7 from HIV negative individuals, did not inhibit HIV-1 activity. Size, charge and immunoreactivity differences between the mucins from HIV negative and positive individuals and among the mucins from HIV patients of different CD4 count was observed by SDS-PAGE, Western blot and ELISA.

Conclusions: Purified salivary mucins from HIV positive patients do not inhibit the AIDS virus in an in vitro assay. Although the reason for the inability of mucins from infected individuals to inhibit the virus is not known, it is likely that there is an alteration of the glycosylation pattern, and therefore of charge of mucin, in HIV positive patients. The ability to inhibit the virus by aggregation by sugar chains is thus diminished.

Show MeSH

Related in: MedlinePlus

Anti-HIV-1 activities of salivary MUC5B and MUC7 of different CD4 counts for filtrates. The rest is as for Fig 1.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2967540&req=5

Figure 2: Anti-HIV-1 activities of salivary MUC5B and MUC7 of different CD4 counts for filtrates. The rest is as for Fig 1.

Mentions: To determine if the salivary MUC5B and MUC7 mucins from HIV positive patients trap or aggregate the viruses as the MUC5B and MUC7 mucins from HIV negative individuals did [4] the mixtures were filtered through 0.45 μm pore size cellulose acetate filter at the end of the incubation period (60 min), and the filtrates were subsequently incubated with the CEM SS cells for 30 min. Unlike the filtrates from the mixtures of HIV-1 plus MUC5B and MUC7 from HIV negative individuals [4], these filtrates caused 100% viral infection of the CEM SS cells (Figure 2A, B and 2C). Even if these filtrates were incubated with the CEM SS cells for 1 h and 2 h, no change from the above results was observed (Figure 2A, B and 2C).


Anti-HIV-1 activity of salivary MUC5B and MUC7 mucins from HIV patients with different CD4 counts.

Habte HH, de Beer C, Lotz ZE, Roux P, Mall AS - Virol. J. (2010)

Anti-HIV-1 activities of salivary MUC5B and MUC7 of different CD4 counts for filtrates. The rest is as for Fig 1.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2967540&req=5

Figure 2: Anti-HIV-1 activities of salivary MUC5B and MUC7 of different CD4 counts for filtrates. The rest is as for Fig 1.
Mentions: To determine if the salivary MUC5B and MUC7 mucins from HIV positive patients trap or aggregate the viruses as the MUC5B and MUC7 mucins from HIV negative individuals did [4] the mixtures were filtered through 0.45 μm pore size cellulose acetate filter at the end of the incubation period (60 min), and the filtrates were subsequently incubated with the CEM SS cells for 30 min. Unlike the filtrates from the mixtures of HIV-1 plus MUC5B and MUC7 from HIV negative individuals [4], these filtrates caused 100% viral infection of the CEM SS cells (Figure 2A, B and 2C). Even if these filtrates were incubated with the CEM SS cells for 1 h and 2 h, no change from the above results was observed (Figure 2A, B and 2C).

Bottom Line: Cells were then cultured and viral replication was measured by a qualitative p24 antigen assay.The size, charge and immunoreactivity of mucins from HIV negative and positive individuals was also analysed by SDS-PAGE, Western blot and ELISA respectively.Size, charge and immunoreactivity differences between the mucins from HIV negative and positive individuals and among the mucins from HIV patients of different CD4 count was observed by SDS-PAGE, Western blot and ELISA.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Surgery, Division of General Surgery, University of Cape Town, Observatory, Cape 7925, South Africa.

ABSTRACT

Background: We have previously shown that MUC5B and MUC7 mucins from saliva of HIV negative individuals inhibit HIV-1 activity by 100% in an in vitro assay. The purpose of this subsequent study was to investigate whether MUC5B and MUC7 from saliva of HIV patients or with full blown AIDS had a similar inhibitory activity against the virus.

Methods: Salivary MUC5B and MUC7 from HIV patients with different CD4 counts (< 200, 200-400 and > 400) were incubated with HIV-1 prior to infection of the human T lymphoblastoid cell line (CEM SS cells). Cells were then cultured and viral replication was measured by a qualitative p24 antigen assay. The size, charge and immunoreactivity of mucins from HIV negative and positive individuals was also analysed by SDS-PAGE, Western blot and ELISA respectively.

Results: It was shown that irrespective of their CD4 counts both MUC5B and MUC7 from HIV patients, unlike the MUC5B and MUC7 from HIV negative individuals, did not inhibit HIV-1 activity. Size, charge and immunoreactivity differences between the mucins from HIV negative and positive individuals and among the mucins from HIV patients of different CD4 count was observed by SDS-PAGE, Western blot and ELISA.

Conclusions: Purified salivary mucins from HIV positive patients do not inhibit the AIDS virus in an in vitro assay. Although the reason for the inability of mucins from infected individuals to inhibit the virus is not known, it is likely that there is an alteration of the glycosylation pattern, and therefore of charge of mucin, in HIV positive patients. The ability to inhibit the virus by aggregation by sugar chains is thus diminished.

Show MeSH
Related in: MedlinePlus